Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination – New England Journal of Medicine Related: U.S. regulators pause Johnson & Johnson vaccine rollout over rare (1 in a million) cases of blood clots AND 4 Things to Know About the J&J Covid Vaccine Pause – Kaiser Health News AND Why Johnson & Johnson shots were paused — and […]
The post Case Report: Thrombotic Thrombocytopenia after Johnson & Johnson Vaccine appeared first on Links Medicus.
Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil – Science Commentary: The P.1 coronavirus variant is twice as transmissible as earlier strains – ScienceNews
The post Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil – “we estimate that P.1 may be 1.7–2.4-fold more transmissible” appeared first on Links Medicus.
Study 1: Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study – The Lancet Public Health Study 2: Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study – The Lancet Infectious Diseases Commentaries: Expert reaction to two […]
The post New studies suggest SARS-CoV-2 variant B.1.1.7 is not more deadly, just more transmissible appeared first on Links Medicus.
Why would a Covid vaccine cause rare blood clots? Researchers have found clues – STAT Related: How could a COVID vaccine cause blood clots? Scientists race to investigate – Nature
The post Why would a Covid vaccine cause rare blood clots? Researchers have found clues appeared first on Links Medicus.
Joint CDC and FDA Statement on Johnson & Johnson COVID-19 Vaccine – U.S. Food & Drug Administration Commentaries: Covid-19: US suspends Johnson and Johnson vaccine rollout over blood clots – BMJ AND CDC and FDA recommend US pause use of Johnson & Johnson’s Covid-19 vaccine over blood clot concerns – CNN AND US halts J&J […]
The post U.S. regulators pause Johnson & Johnson vaccine rollout over rare (1 in a million) cases of blood clots appeared first on Links Medicus.
Tobacco Taxes Are Most Effective Yet Least Implemented Tactics, Says WHO – Health Policy Watch Guidance: WHO technical manual on tobacco tax administration – World Health Organization
The post Tobacco Taxes Are Most Effective Yet Least Implemented Tactics, Says WHO appeared first on Links Medicus.
Postoperative In-Hospital Morbidity and Mortality of Patients With COVID-19 Infection Compared With Patients Without COVID-19 Infection – JAMA Network Open Related: Guideline: SARS‐CoV‐2 infection, COVID‐19 and timing of elective surgery AND Study from 116 countries suggests surgery should be delayed for at least seven weeks following a COVID-19 diagnosis to reduce mortality risk
The post Cohort study: Postoperative in-hospital mortality of patients with COVID-19 infection was more than double that in patients without COVID-19 appeared first on Links Medicus.
They Tested Negative for Covid. Still, They Have Long Covid Symptoms. – Kaiser Health News Commentary on Twitter Scary: Many people have tested negative for SARSCoV2, yet they developed Long Covid. What's to blame? Haphazard testing protocols, delays & difficulties accessing tests & poor quality of many of the tests on the market. All […]
The post Perspective | They Tested Negative for Covid. Still, They Have Long Covid Symptoms. appeared first on Links Medicus.
China considers mixing COVID-19 vaccines to boost protection rate – Reuters
The post China considers mixing COVID-19 vaccines to boost protection rate appeared first on Links Medicus.
Phase 3 prevention trial showed 81% reduced risk of symptomatic SARS-CoV-2 infections with subcutaneous administration of REGEN-COV™ (Casirivimab with Imdevimab) – Regeneron Commentaries: Regeneron says antibody cocktail prevented Covid when given as simple injection, not an IV – STAT AND Regeneron’s Covid mAb as a prophylactic injection: Reduced risk of symptomatic infection by 81% – […]
The post [Press release – not published yet] Phase 3 prevention trial showed 81% reduced risk of symptomatic SARS-CoV-2 infections with subcutaneous administration of monoclonal antibodies appeared first on Links Medicus.